# US 2015/0104430 A1 · Methods and Compositions for Generating Pancreatic Progenitors and Functional Beta Cells from hPSCs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104430 A1
- Document ID: US20150104430A1
- Status: Published application
- Kind: A1
- Application number: 14/397,657
- Filed: 2013-04-30
- Published: 2015-04-16
- Earliest claimed: 2012-04-30
- Assignees: University Health Network
- Applicants: University Health Network
- Inventors: Gordon Keller; Maria Cristina Nostro; Audrey Holtzinger; Farida Sarangi
- Web page: https://patentgrep.com/patent/US20150104430A1

## CPC

- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0676: {Pancreatic cells}
- C12N 2500/38: Vitamins
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/40: Regulators of development
- C12N 2501/415: Wnt; Frizzeled
- C12N 2502/28: Vascular endothelial cells
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least one endodermal cell into a NKX6-1+ pancreatic progenitor cell, the combination optionally further comprising at least one Noggin component.

## Claims

### Claim 1

A method of producing NKX6-1+ pancreatic progenitor cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least a portion of the endodermal cell population into NKX6-1+ pancreatic progenitor cells, the combination optionally further comprising at least one Noggin component.

### Claim 2 (depends on 1)

The method of claim 1 wherein the Noggin component comprises one or more of Noggin and/or active conjugates and/or fragments thereof; BMPR1A and/or active conjugates and/or fragments thereof; BMPR1B and/or active conjugates and/or fragments thereof; Dorsomorphin and/or salts or solvates thereof; LDN 193189, also known as “DM-3189”, and/or salts and/or solvates thereof; CHORDIN and/or active conjugates and/or fragments thereof; and/or any combination of two or more thereof, optionally wherein the Noggin component is Noggin.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1 wherein the EGF component comprises EGF and/or active conjugates and/or fragments thereof; Amphiregulin (AR) and/or active conjugates and/or fragments thereof; Transforming Growth Factor α (TGFα) and/or active conjugate and/or fragments thereof; Betacellulin (BTC) and/or active variants and/or fragments thereof; Epiregulin (EPR) and/or active variants and/or fragments thereof; Neuregulins (including for example NRG1, NRG2, 3 NRG4) and/or active variants and/or fragments thereof; and/or combinations of two or more thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the EGF component is EGF and/or an active conjugate and/or fragment thereof, optionally wherein the EGF conjugate is Heparin-binding EGF (HB-EGF).

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the Nicotinamide component comprises nicotinamide (also known as niacinamide and nicotinic acid amide), salts, solvates and conjugates thereof; Poly(ADP-ribose) synthetase inhibitors such as benzamide and/or 3-aminobenzamide; Sir-2 inhibitors such as sirtinol, M15, splitomicin; HDAC inhibitors such as AN-9, CI-994, FK228, LAQ-824, MS275, SAHA, Valproic Acid, TSA, Sodium Butyrate, and/or combinations of two or more thereof, optionally wherein the Nicotinamide component is Nicotinamide and/or a salt, solvate and/or conjugate thereof.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the combination of at least one Noggin component, at least one EGF component, and at least one nicotinamide component comprises Noggin, EGF and nicotinamide (e.g. NENA).

### Claim 10 (depends on 1)

The method of claim 1, further comprising an Exendin-4 component, optionally wherein the Exendin-4 component is Exendin-4.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the endodermal cell population is differentiated from pluripotent stem cells (PSCs) such as an embryonic stem cell (ESC) or an induced pluripotent stem cells (iPSCs), optionally wherein the pluripotent stem cell is a human ESC (hESC) or a human iPSC (hiPSC).

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, first comprising producing an endodermal cell population.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method of producing the endodermal cell population comprises one or more of steps (or substeps) a, b and c; and step d, the steps comprising:
a) contacting a pluripotent stem cell population with a combination of:
I) a nodal agonist, optionally ActA and a wnt signaling agonist, optionally Wnt3a or CIHR 99021,
II) a nodal agonist, optionally Act A, a FGF agonist, optionally bFGF and optionally a wnt signaling agonist, optionally Wnt3a CIHR 99021; and
III) a nodal agonist, optionally ActA and a FGF agonist, optionally bFGF;
to produce Stage 1 differentiated cells;
b) contacting the Stage I differentiated cells with a FGF agonist, optionally FGF10, and optionally wnt signaling agonist, optionally Wnt3a and/or a noggin component, optionally Dorsomorphin, to produce Stage 2 differentiated cells;
c) contacting the Stage 2 differentiated cells with a Noggin component, optionally Noggin, Retinoic acid (RA) or RA analog, and optionally cyclopamine-KAAD (Cyc), a FGF agonist, optionally FGF10 and/or an Exendin-4 component, optionally Exendin-4 to provide a endodermal cell population; and
d) contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination comprising at least one EGF component and at least one nicotinamide component in an amount sufficient to induce the differentiation of at least a portion of the endodermal cell population into NKX6-1+ pancreatic progenitor cells.

### Claim 16 (depends on 1)

A method for generating a NKX6-1+ insulin producing cell population comprising:
a. producing a population of cells comprising NKX6-1 positive pancreatic progenitor cells according to the method of claim 1; and
b. introducing the population of cells, or an NKX6-1 enriched or isolated population, into a subject.

### Claim 17 (depends on 1)

A method for generating an insulin producing cell comprising:
a. generating a population of cells comprising NKX6-1 positive pancreatic progenitor cells, optionally produced according to the method of claim 1;
b. co-culturing the NKX6-1 positive pancreatic progenitor cells with CD34+ endothelial cells.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1 comprising enriching or isolating a NKX6-1 positive population of cells.

### Claim 20 (depends on 19)

The method of claim 19, wherein the enriching or isolating step comprises contacting the population of cells with an HPx epitope detecting antibody and isolating or partially purifying the HPx1 and/or HPx2 bound subpopulation of cells, optionally wherein the HPx epitope detecting antibody is HPx1 and/or HPx2.

### Claim 21

(canceled)

### Claim 22 (depends on 19)

An enriched and/or isolated NKX6-1 positive cell population produced according to the method of claim 19 and/or a composition comprising said cell population and a suitable diluent.

### Claim 23 (depends on 22)

The enriched NKX6-1 positive cell population of claim 22 comprising at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or up to about 95% NKX6-1 positive cells.

### Claim 24 (depends on 23)

The isolated NKX6-1 positive cell population of claim 23, comprising at least 30%, 35%, 40% or at least 50% NKX6-1 positive pancreatic progenitor cells and/or comprising at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or up to about up to 95% NKX6-1 positive insulin producing cells.

### Claim 25

(canceled)

### Claim 26

A culture medium supplement composition comprising an EGF component, a Nicotinamide component and optionally a Noggin component and/or an Exendin-4 component.

### Claim 27 (depends on 26)

A culture medium culture composition comprising a suitable base culture medium and the culture medium supplement composition of claim 26.

### Claim 28

A kit comprising:
an EGF component,
a Nicotinamide component; and/or
a Noggin component and/or
optionally an Exendin-4 component.

### Claim 29

(canceled)
